IL17A and psoriasis: The dose–response study of B. breve in a mice psoriasis model by Chen et al. showed significantly reduced IL-17 and TNF-alpha levels and improved gut microbiota following a high (109 or 1010 cfu) compared with a low dose (106,107 or 108 cfu) of the probiotic.